Nanosphere’s Verigene BC-GP Decreases Patient Length of Stay

Nanosphere, Inc. (NASDAQ:NSPH) announced publication of a study that demonstrates the clinical and economic impact of implementing rapid sepsis diagnostic testing with the Company’s FDA-cleared Verigene® Gram-Positive Blood Culture Test (BC-GP) in a pediatric patient population.
According to Jennifer Dien Bard, Ph.D., D (ABMM), FCCM, Director of the Clinical Microbiology Laboratory at Children’s Hospital Los Angeles

Our study is the first to assess the clinical and economic impact of BC-GP in a pediatric population. We saw a decrease in morbidity, mortality, length of stay, and hospital costs for pediatric patients with gram-positive bloodstream infections after implementing BC-GP.

Click here to view the full press release.